Infection with influenza virus in humans results in the appearance of antibodies to the hemagglutinin (HA) or neuraminidase or both in both serum and nasal secretions (for reviews, see references 8 and 31). Although antibodies found in nasal secretions are primarily of the immunoglobulin A (IgA) isotype, antibodies of the IgM, IgG, and IgA isotypes are detectable in serum (3, 24) .
Human IgA is represented by two subclasses (IgAl and IgA2) and two molecular forms (polymeric and monomeric) with characteristic distributions in various body fluids. Serum IgA occurs predominantly in the monomeric form and has a relatively larger proportion of IgAl molecules than do external secretions, which contain almost exclusively polymeric IgA and have a nearly equal distribution of IgAl and IgA2 (5, 10, 12, 32, 33) . Unlike the IgG subclasses (22, 25) , the distribution of specific antibodies within the IgA subclasses has not been extensively studied. Furthermore, the distribution of antibody activity with respect to polymeric and monomeric IgA has not been established. The kinetics, magnitude, and persistence of an IgA-associated immune response in serum and secretions depends on the route of immunization and the form of the antigen, i.e., soluble versus particulate or living versus killed.
The study of a virus that infects mucosal surfaces provides a model which can be used for the elucidation of the probable origin(s) of serum and secretory IgA antibodies and may ultimately be helpful in determining the most efficient routes of immunization. Although serum antibodies can be correlated with protection against infection with influenza virus, the presence of secretory IgA antibodies in secretions of the upper respiratory tract (24) , particularly those directed towards the HA determinants, is thought to be a major determinant of immunity (3, 4, 7, 8, 23, 24, 31 ington, D.C. (28) . The HA of this virus is closely related to that of the A/Peking/2/79 (H3N2) virus used as the infecting agent in this study (3) . Human myeloma IgAlX (Git) and IgA2X (Fel) proteins and secretory component (SC) were isolated and purified as previously described (16) . Mouse monoclonal human IgA subclass antibodies were labeled with 1251 by the lactoperoxidase method (20) .
Strips of polystyrene wells (Immulon I; Dynatech Laboratories, Inc., Alexandria, Va.) were coated overnight with HA at 0.1 ,ug/ml in 0.05 M carbonate-bicarbonate buffer (pH 9.6). The assay was performed as previously described (2) except that 1% bovine serum albumin in 0.01 M phosphatebuffered saline (pH 7.4) was used for blocking, for washing, and as the diluent. The fractions were applied to HA-coated and uncoated blocked wells, followed by '25I-labeled affinity-purified mouse monoclonal human IgAl or IgA2 antibodies. These antibodies have been shown to be specific for human IgAl and IgA2, respectively, regardless of light-chain type or IgA2 allotype (9) .
Because of the lack of purified human anti-HA IgAl and IgA2 standards, a method of standardization which most closely mimicked the antigen-binding assay was used. Wells were coated with rabbit anti-human X chain, followed by the application of purified human myeloma IgAlX (Git) actually decreased slightly, even in the presence of a large increase in IgAl antibody levels.
In serum (Fig. 2) , the levels of IgA2 HA antibodies were surprisingly low. The previously reported data concerning the distribution of total IgAl and IgA2 in normal human serum indicate an average ratio of about 80% IgAl to 20% IgA2 (5, 10, 12, 32) . These findings indicate a selective increase of IgAl HA antibodies rather than a proportional increase of both subclasses.
Molecular form of IgA HA antibodies. Nasal wash and serum samples were fractionated by high-pressure liquid chromatography on a size exclusion column and assayed by radioimmunoassay. Both the IgAl and IgA2 antibody activities in nasal wash specimens were composed entirely of polymers and appeared to be secretory IgA, as there was no binding of radiolabeled SC (Fig. 3) . SC is known to bind in vitro to polymeric J-chain-containing IgA but not to secretory IgA (19, 26, 30) . These results were not unexpected because ca. 95% of the total IgA in human secretions, such as colostrum, is polymeric and contains SC (16, 33) . In contrast, normal human serum IgA is predominantly monomeric (85 to 90%) (10, 16, 26, 33) . However, the profile of serum IgAl revealed a disproportionately large amount of polymeric IgA (Fig. 4, closed circles) . IgA2 antibody activity could not be determined on high-pressure liquid chromatographic fractions of serum owing to its initial low concentration and the dilution (1:100) which occurred during chromatography. To (Fig. 4, open circles) . This indicated that the putative polymer was in fact J-chaincontaining polymeric IgA, as nonspecifically aggregated monomeric IgA does not bind SC (19, 30 (Fig. 4, triangles) , whereas SC-binding activity now eluted exclusively in the void volume, corresponding to the elution position of IgM (Fig. 4, plus  symbols) . At least one serum sample from each of the 13 subjects was fractionated and analyzed for IgA HA antibodies. Although the proportions of polymer to monomer varied, there was always a higher proportion of polymer to monomer in the postinfection samples than one would expect from the ratios of total polymer to monomer found in normal human serum (10, 16, 26, 33 antigen encounter when bronchus-or gut-associated lymphoid tissues are stimulated (for a review, see reference 21). In humans, infection with a replicating antigen such as influenza virus antigen also leads to a systemic immune response manifested by the presence of serum antibodies of the IgM, IgG, and IgA isotypes (3, 24) . IgA antibodies in human secretions originate mostly from submucosal plasma cells and are selectively transported by an SC-mediated mechanism. In the absence of inflammation, only a small proportion of IgA in secretions is derived from the circulation (11; L. F. Bertoli, H. Kubagawa, W. J. Koopman, J. Mestecky, and M. D. Cooper, Fed. Proc. 42:840, 1983). Because the IgA HA antibodies detected in nasal secretions from volunteers examined in this study were polymeric and failed to bind 125I-SC, we conclude that they represent true SC-containing secretory IgA.
The origin of IgA HA antibodies in serum is less obvious. The parallel rise in IgA antibodies in serum and secretions observed in individuals undergoing primary as well as secondary infections with influenza A virus (3, 24) has been taken as evidence for a common mucosal origin of both serum and secretory IgA antibodies (3). Human serum IgA, which is of predominantly monomeric form, originates primarily from tissues such as bone marrow, spleen, and lymph nodes (17, 18) . The polymeric form of serum IgA antibodies to HA further suggests that these antibodies detectable in the circulation were derived from secretory tissues known to produce polymeric IgA (1, 15) and escaped the transport process operational in secretory glands. The true polymeric nature of the IgA was demonstrated by the elution position of the IgA antibodies on a standardized size exclusion column and by the ability of the high-molecular-weight fractions to bind SC. The only serum proteins capable of binding SC are polymeric IgA and IgM (19, 26, 30) The residual SC binding was presumably due to IgM as ascertained by the elution position on a standardized column, its antibody activity (as evidenced by its ability to bind to an HA-coated plate), and the resistance of IgM to IgAl protease cleavage. The polymeric IgA antibodies detected in serum could have originated in the nasal mucosa or in remote mucosal tissues seeded by cells derived from bronchus-or gut-associated lymphoid tissues or in both. Previous studies have indeed shown that human milk contains antibodies to influenza virus (27) , and oral ingestion of virus leads to the appearance of specific IgA antibodies in nasal secretions (34) . We cannot exclude the possibility that HA might have the unique property of stimulating the production of only polymeric IgA even in tissues which are known to produce predominantly monomeric IgA.
Although serum antibodies to the HA antigen were almost exclusively of the IgAl subclass, analyses of nasal washes from infected individuals revealed that the HA antibodies in those washes were of both IgA subclasses. However, as in serum, there was a selective increase in the IgAl subclass. In other recent reports, serum IgA antibodies to cytomegalovirus (17) and phosphorycholine, P-lactoglobulin, and tetanus toxoid (6) were detected in both IgA subclasses; external secretions were not examined. It has recently been demonstrated that the nature of the antigen may also influence the subclass distribution of IgA antibodies. For example, salivary antibodies to microbial protein and carbohydrate antigens are predominantly of the IgAl subclass, whereas those to lipoteichoic acid or lipopolysaccharides are predominantly IgA2 (T. A. Brown and J. Mestecky, Infect. Immun., in press). It is apparent from the present study that a different IgA subclass distribution of specific antibodies may be found when external secretions are examined in addition to serum.
Bacteria that colonize the upper respiratory tract, such as H. influenza, Streptococcus pneumoniae, and Neisseria meningitidis, are capable of producing proteases specific for the hinge regions of human IgAl proteins (14, 29) . If the anti-HA response, which is thought to be the major determinant of protection against influenza A virus, occurs primarily in the IgAl subclass, there is a greater potential for interference with local immunity by such proteases. Significant levels of antibodies to HA in the protease-resistant IgA2 subclass would therefore be desirable to provide compensatory protection. Although IgA2 constitutes ca. 15 to 20% of total serum IgA (5, 10, 12, 32) and although we were able to demonstrate HA antibodies of the IgA2 subclass in nasal washes, the levels of IgA2 antibodies to HA in serum were lower than expected. It is possible that polymeric IgA2 produced locally in secretory tissues does not enter the circulation in significant quantities, is preferentially transported into secretions, or is catabolized faster than polymeric IgAl or monomeric serum IgA of both subclasses. Studies are in progress to determine the molecular form and subclass of IgA HA antibodies in volunteers receiving a parenteral, inactivated vaccine which, assuming HA does not uniquely stimulate polymer production, would more likely lead to the appearance of monomeric IgA antibodies in serum.
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